c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
作者： C Carlomagno , F Perrone , C Gallo , M De Laurentiis , R Lauria
DOI: 10.1200/JCO.1996.14.10.2702
关键词:
摘要: PURPOSEWe studied retrospectively the interaction between c-erbB2 overexpression and adjuvant tomoxifen in node-negative breast cancer patients enrolled Gruppo Universitario Napoletano 1 (GUN-1) trial.PATIENTS AND METHODSc-erbB2, evaluated by immunohistochemistry 145 of 173 randomly assigned to 2-year tamoxifen or no further therapy, was considered overexpressed if greater than 10% cells showed specific membrane staining. The role each prognostic variable their independent effect were using Cox model. Disease-free (DFS) overall (OAS) survival curves estimated Kaplan-Meier method.RESULTSAs November 30, 1994, median follow-up period 12 years. 43 (29.7%), which directly correlated with tumor size inversely estrogen receptor (ER) level. At univariate analysis, did not affect either DFS OAS; had a on reducing risk rec...
elsevier.com
sci-hub.se 参考文章(28)
M D Pegram, R J Pietras, S B Howell, V R Chazin, B M Fendly, D J Slamon, Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. ,vol. 9, pp. 1829- 1838 ,(1994)
H J G Bloom, W W Richardson, Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. British Journal of Cancer. ,vol. 11, pp. 359- 377 ,(1957) , 10.1038/BJC.1957.43
David R. Cox, Regression Models and Life-Tables Springer Series in Statistics. ,vol. 34, pp. 527- 541 ,(1992) , 10.1007/978-1-4612-4380-9_37
Angelo Raffaele Bianco, Ciro Gallo, Alfredo Marinelli, Michela D'Istria, Sabino De Placido, Clorindo Pagliarulo, Giuseppe Petrella, Giovanni Delrio, Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study. The Lancet. ,vol. 332, pp. 1095- 1099 ,(1988) , 10.1016/S0140-6736(88)90521-1
B A Gusterson, R D Gelber, A Goldhirsch, K N Price, J Säve-Söderborgh, R Anbazhagan, J Styles, C M Rudenstam, R Golouh, R Reed, Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. Journal of Clinical Oncology. ,vol. 10, pp. 1049- 1056 ,(1992) , 10.1200/JCO.1992.10.7.1049
S Paik, R Hazan, E R Fisher, R E Sass, B Fisher, C Redmond, J Schlessinger, M E Lippman, C R King, Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. Journal of Clinical Oncology. ,vol. 8, pp. 103- 112 ,(1990) , 10.1200/JCO.1990.8.1.103
J. Hanson, B. E. Krause, W. A. McBlain, K. D. Dietrich, N. Jamil, J. Danyluk, H. Jenkins, A. H. G. Paterson, A. W. Lees, M. C. Paterson, R. M. Fourney, D. J. Slamon, Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Research. ,vol. 51, pp. 556- 567 ,(1991)
D C Allred, G M Clark, A K Tandon, R Molina, D C Tormey, C K Osborne, K W Gilchrist, E G Mansour, M Abeloff, L Eudey, HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. Journal of Clinical Oncology. ,vol. 10, pp. 599- 605 ,(1992) , 10.1200/JCO.1992.10.4.599
K Leitzel, Y Teramoto, K Konrad, V M Chinchilli, G Volas, H Grossberg, H Harvey, L Demers, A Lipton, Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. Journal of Clinical Oncology. ,vol. 13, pp. 1129- 1135 ,(1995) , 10.1200/JCO.1995.13.5.1129
S Toikkanen, H Helin, J Isola, H Joensuu, Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. Journal of Clinical Oncology. ,vol. 10, pp. 1044- 1048 ,(1992) , 10.1200/JCO.1992.10.7.1044